Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Figlin

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
CA: a Cancer Journal for Clinicians|September 1, 1996
Current management of renal cell carcinomaM H Sokoloff, J B deKernion, R A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinomaR A Figlin, A Belldegrun, N Moldawer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?R A Figlin, B C Leibovich, G D Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Validation of the ucla integrated staging system for patients with renal cell carcinomaA Zisman, A J Pantuck, R A Figlin, et al.
Cancer|July 15, 1991
Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatmentH J Ross, L A Moy, R Kaplan, et al.
Seminars in Oncology|April 18, 2000
Adoptive cellular therapyD M Hoffman, B J Gitlitz, A Belldegrun, et al.
JAMA|January 20, 1984
Kaposi's sarcoma and immunoblastic sarcoma in the acquired immune deficiency syndromeR A Figlin, J D Moriguchi, R A Coffey, et al.
Current Oncology (Toronto, Ont.)|April 17, 2009
Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approachS K Pal, R K Gupta, G Dosik, et al.
Seminars in Oncology|October 1, 1991
The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinomaR A Figlin, A S Abi-Aad, A Belldegrun, et al.
Seminars in Oncology|October 1, 1991
Renal cell carcinoma: basic biology and current approaches to therapyA Belldegrun, A S Abi-Aad, R A Figlin, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
CA: a Cancer Journal for Clinicians|September 1, 1996
Current management of renal cell carcinomaM H Sokoloff, J B deKernion, R A Figlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinomaR A Figlin, A Belldegrun, N Moldawer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?R A Figlin, B C Leibovich, G D Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Validation of the ucla integrated staging system for patients with renal cell carcinomaA Zisman, A J Pantuck, R A Figlin, et al.
Cancer|July 15, 1991
Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatmentH J Ross, L A Moy, R Kaplan, et al.
Seminars in Oncology|April 18, 2000
Adoptive cellular therapyD M Hoffman, B J Gitlitz, A Belldegrun, et al.
JAMA|January 20, 1984
Kaposi's sarcoma and immunoblastic sarcoma in the acquired immune deficiency syndromeR A Figlin, J D Moriguchi, R A Coffey, et al.
Current Oncology (Toronto, Ont.)|April 17, 2009
Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approachS K Pal, R K Gupta, G Dosik, et al.
Seminars in Oncology|October 1, 1991
The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinomaR A Figlin, A S Abi-Aad, A Belldegrun, et al.
Seminars in Oncology|October 1, 1991
Renal cell carcinoma: basic biology and current approaches to therapyA Belldegrun, A S Abi-Aad, R A Figlin, et al.
Pageof 9